Omeros researches and develops small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. Their first FDA-approved drug, Omidria, is used during cataract surgery and intraocular lens replacement. Omeros has multiple clinical-stage development programs, including those focused on Huntington's disease, schizophrenia, and cognitive impairment. They also have a proprietary GPCR platform that provides new drug targets to the pharmaceutical industry. Omeros aims to improve patient outcomes by modulating the molecular mechanisms of pathologic conditions.